IL6R and metabolic dysfunction-associated steatotic liver disease: This target-based MR analysis gave novel insights into the increased risk of NAFLD when inhibiting the IL-6 signaling pathway via IL-6R blockade, especially inhibiting the classic IL-6 signaling pathway.